RxDoctor Payments Data

Howard Loveless, MD

Otolaryngology · New Bern, NCNPI 1467427757

Payments from drug & device makers

$1,930in general payments, 2019–2025

Across 82 payments — averaging $23.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$481
  • Sanofi$474
  • Regeneron Healthcare Solutions, Inc.$235
  • Aerin Medical Inc.$187
  • Inspire Medical Systems, Inc.$80
  • Stryker$79
  • plus $394 from 14 others

What the payments were for

  • Food & beverage$1,930100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,930 in reported general payments places this provider in the 65th percentile of 362 otolaryngology providers in North Carolina.

See all otolaryngology providers in North Carolina

Medicare billing

Part B allowed, 2024
$104,980
Medicare patients
431
Services billed
1,661

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Ipratropium Bromide152$3,694
Epinephrine14$2,729
Ciprofloxacin-DexamethasoneCiprofloxacin Hcl/Dexameth18$2,402
Pilocarpine Hcl27$1,693
Fluocinolone Acetonide Oil36$1,560
Fluticasone Propionate HfaFluticasone Propionate11$1,362
Pentoxifylline55$1,262
Azelastine Hcl25$701
Fluticasone Propionate32$614
Hydrochlorothiazide244$600
Amitriptyline Hcl27$456
Clarithromycin15$382
Clindamycin Hcl23$341
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav20$281
Gabapentin24$237

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Hikma Pharmaceuticals USAEpinephrine$24$2,72914 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 362 otolaryngology providers in North Carolina.

Other otolaryngology in New Bern

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →